全文获取类型
收费全文 | 33174篇 |
免费 | 2322篇 |
国内免费 | 55篇 |
专业分类
耳鼻咽喉 | 303篇 |
儿科学 | 1181篇 |
妇产科学 | 962篇 |
基础医学 | 4276篇 |
口腔科学 | 430篇 |
临床医学 | 4350篇 |
内科学 | 5946篇 |
皮肤病学 | 471篇 |
神经病学 | 3537篇 |
特种医学 | 596篇 |
外国民族医学 | 4篇 |
外科学 | 2973篇 |
综合类 | 328篇 |
一般理论 | 45篇 |
预防医学 | 4616篇 |
眼科学 | 507篇 |
药学 | 2209篇 |
中国医学 | 23篇 |
肿瘤学 | 2794篇 |
出版年
2024年 | 44篇 |
2023年 | 293篇 |
2022年 | 517篇 |
2021年 | 1119篇 |
2020年 | 679篇 |
2019年 | 1035篇 |
2018年 | 1157篇 |
2017年 | 832篇 |
2016年 | 979篇 |
2015年 | 1005篇 |
2014年 | 1328篇 |
2013年 | 1870篇 |
2012年 | 2734篇 |
2011年 | 2953篇 |
2010年 | 1545篇 |
2009年 | 1296篇 |
2008年 | 2376篇 |
2007年 | 2376篇 |
2006年 | 2173篇 |
2005年 | 2042篇 |
2004年 | 1825篇 |
2003年 | 1575篇 |
2002年 | 1594篇 |
2001年 | 210篇 |
2000年 | 173篇 |
1999年 | 200篇 |
1998年 | 307篇 |
1997年 | 238篇 |
1996年 | 168篇 |
1995年 | 178篇 |
1994年 | 134篇 |
1993年 | 119篇 |
1992年 | 69篇 |
1991年 | 47篇 |
1990年 | 48篇 |
1989年 | 39篇 |
1988年 | 39篇 |
1987年 | 35篇 |
1986年 | 33篇 |
1985年 | 16篇 |
1984年 | 19篇 |
1983年 | 29篇 |
1982年 | 24篇 |
1981年 | 18篇 |
1980年 | 11篇 |
1978年 | 4篇 |
1977年 | 4篇 |
1973年 | 4篇 |
1972年 | 3篇 |
1942年 | 4篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
101.
Stafford Jade D. Goggins Emily R. Lathrop Eva Haddad Lisa B. 《Maternal and child health journal》2021,25(4):599-605
Maternal and Child Health Journal - Many studies correlate lower health literacy with poorer health outcomes and inferior provider-patient communication. Little is known about how impaired health... 相似文献
102.
DeMarco Mario P. Shafqat Maha Horst Michael A. Srinivasan Sukanya Frayne Daniel J. Schlar Lisa Barr Wendy Brooks 《Maternal and child health journal》2021,25(2):207-213
Maternal and Child Health Journal - Each year, 3% of infants in the Unites States (US) are born with congenital anomalies, including 3000 with neural tube defects. Multivitamins (MVIs) including... 相似文献
103.
Ashford Kristin McCubbin Andrea Barnett Janine Blair Lisa M. Lei Feitong Bush Heather Breland Alison 《Maternal and child health journal》2021,25(8):1175-1181
Maternal and Child Health Journal - In the US, approximately 8% of pregnant women smoke, and 5–11.9% currently use ENDS products. The health effects of ENDS use are debated; however, most... 相似文献
104.
Layland Eric K. Caldwell Linda L. Ram Nilam Smith Edward A. Wegner Lisa Jacobs Joachim J. 《Prevention science》2022,23(7):1251-1263
Prevention Science - An earlier trial of a school-based, preventative intervention, HealthWise South Africa, demonstrated some efficacy in preventing adolescent drinking and smoking in the Western... 相似文献
105.
Edwards Katie M. Banyard Victoria L. Waterman Emily A. Mitchell Kimberly J. Jones Lisa M. Kollar Laura M. Mercer Hopfauf Skyler Simon Briana 《Prevention science》2022,23(8):1379-1393
Prevention Science - Involving youth in developing and implementing prevention programs to reduce sexual violence (SV) has the potential to improve prevention outcomes. However, there has been... 相似文献
106.
107.
108.
109.
110.
Gregory A Kline Lisa M Lix William D Leslie 《Journal of bone and mineral research》2021,36(8):1425-1431
The role of mid-treatment monitoring dual-energy X-ray absorptiometry–bone mineral density (DXA-BMD) for bisphosphonate-treated patients with osteoporosis remains unsettled. A common reason for such monitoring is to encourage ongoing medication adherence. We sought to determine if a DXA-BMD treatment monitoring test was associated with improved medication adherence and whether improved adherence after a DXA-BMD treatment monitoring test was associated with subsequent reduction in fracture rates. Using linked administrative databases within Manitoba, Canada, we performed a retrospective cohort study of women starting and continuing antiresorptive therapy in whom a mid-treatment DXA-BMD monitoring test was performed. From the provincial pharmacy database, we estimated medication adherence by calculating annual medication possession ratio (MPR) and determining the change in MPR with respect to change (stable/decrease) in the DXA-BMD monitoring test, in addition to fracture rates before and after the test. The cohort comprised 3418 women, 90.7% treated with oral bisphosphonate, with pharmacy data for the 3 years before and after the mid-treatment DXA-BMD. Median (interquartile range) MPR was 0.84 (0.49–0.99) in the year before DXA-BMD and 0.84 (0.48–0.99) in the year after DXA-BMD (p = 0.37). Among those whose DXA-BMD declined, MPR in the prior year was 0.54 (0.04–0.92) but improved to 0.70 (0.31–0.92) in the year after DXA-BMD (p < 0.001). Among those whose DXA-BMD monitoring test was stable/improved, the fracture rate before the monitoring DXA-BMD was 10.1 per 1000 person-years and in those whose DXA-BMD monitoring test showed a decrease, the rate was 23.7 per 1000 person-years (p < 0.001). Despite improved adherence in those with DXA-BMD decline, the post DXA-BMD fracture rate was 22.4 per 1000 person-years versus 12.9 per 1000 person-years in those who had stable DXA-BMD (p < 0.001). A mid-treatment DXA-BMD reassessment strategy may be useful to focus attention upon adherence, but for optimal fracture outcomes, treatment adherence should be specifically addressed at the commencement of therapy. © 2021 American Society for Bone and Mineral Research (ASBMR). 相似文献